A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patient’s own cells (autologous) and are pre-manufactured, and stored frozen and ready to ship to a patient’s treatment location, making them what we believe to be “off-the-shelf.” Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in SLE with or without lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | - | 33M |
| Net Income | -79M | -65M | - |
| EPS | $-1.24 | $-5.81 | $-35.78 |
| Free Cash Flow | -79M | -56M | -51M |
| ROIC | -1087.8% | -35.0% | - |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.00 | -0.31 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -86M | -67M | -31M |
| Operating Margin | 0.0% | - | -93.2% |
| ROE | -61.3% | -530.9% | - |
| Shares Outstanding | 25M | 11M | 24M |
| Metric | 2023 | ||
|---|---|---|---|
| Income Statement | |||
| Revenue | 33M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -31M | -67M | -86M |
| Op. Margin | -93.2% | N/A | 0.0% |
| Net Income | N/A | -65M | -79M |
| Net Margin | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | N/A | -35.0% | N/M |
| ROE | N/A | -530.9% | -61.3% |
| ROA | N/A | -41.5% | -53.2% |
| Cash Flow | |||
| Op. Cash Flow | -47M | -55M | -77M |
| Free Cash Flow | -51M | -56M | -79M |
| Owner Earnings | -57M | -64M | -86M |
| CapEx | 3.3M | 642K | 2.2M |
| Maint. CapEx | 2.3M | 2.4M | 2.4M |
| Growth CapEx | 992K | 0 | 0 |
| D&A | 2.3M | 2.4M | 2.4M |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 7.1M | 7.0M | 7.0M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | N/A | -185M | -123M |
| Cash & Equiv. | N/A | N/A | 123M |
| Long-Term Debt | N/A | 44K | 44K |
| Debt/Equity | -0.31 | 0.00 | 0.00 |
| Interest Coverage | N/A | N/A | N/A |
| Equity | -162M | 187M | 129M |
| Total Assets | 105M | 210M | 149M |
| Total Liabilities | 51M | 23M | 20M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -181M | -247M | -247M |
| Working Capital | 68M | 176M | 176M |
| Current Assets | 80M | 189M | 189M |
| Current Liabilities | 12M | 12M | 12M |
| Per Share Data | |||
| EPS | -35.78 | -5.81 | -1.24 |
| Owner EPS | -2.33 | -5.73 | -3.51 |
| Book Value | -6.65 | 16.59 | 5.26 |
| Cash Flow/Share | -1.95 | -4.89 | -3.13 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 24.4M | 11.3M | 24.5M |
| Valuation | |||
| P/E Ratio | N/A | N/A | -6.0 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | 0.6 | 1.4 |
| Price/Sales | N/A | N/A | N/A |
| FCF Yield | N/A | -46.5% | -42.9% |
| Market Cap | N/A | 120M | 184M |
| Avg. Price | N/A | 11.85 | 7.49 |
| Year-End Price | N/A | 10.64 | 7.49 |
Artiva Biotherapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Artiva Biotherapeutics, Inc. (ARTV) has a 5-year average return on invested capital (ROIC) of -35.0%. This is below average and may indicate limited pricing power.
Artiva Biotherapeutics, Inc. (ARTV) has a market capitalization of $184M. It is classified as a small-cap stock.
Artiva Biotherapeutics, Inc. (ARTV) does not currently pay a regular dividend.
Artiva Biotherapeutics, Inc. (ARTV) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Artiva Biotherapeutics, Inc. (ARTV) generated $-56 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Artiva Biotherapeutics, Inc. (ARTV) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Artiva Biotherapeutics, Inc. (ARTV) reported earnings per share (EPS) of $-5.81 in its most recent fiscal year.
Artiva Biotherapeutics, Inc. (ARTV) has a return on equity (ROE) of -530.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for Artiva Biotherapeutics, Inc. (ARTV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Artiva Biotherapeutics, Inc. (ARTV) has a book value per share of $16.59, based on its most recent annual SEC filing.